Talquetamab Plus Daratumumab Improves PFS in Relapsed/Refractory Myeloma
In MonumenTAL-3, talquetamab plus daratumumab with or without pomalidomide significantly improved PFS vs DPd in relapsed/refractory myeloma....
News Desk
Staff Writer
Published
Jun 14, 2026
Source
CancerNetwork
Analytics
0 0 0

AI Insight:This story is currently being processed. Visit Plainscan for the latest updates.
Our news engine is processing this article. Please visit the source link to read the full story.